Genor Biopharma Holdings Ltd. has announced a further delay in the dispatch of its circular related to several key transactions, including a very substantial acquisition and a proposed merger. The delay pertains to the financial reporting for the period ending December 2024. The announcement does not specify the form type for the delayed financial report.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.